| Erlotinib Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT01664897) | M.D. Anderson Cancer Center | 2013-05-16 |
| Cytarabine With or Without SCH 900776 in Treating Adult Patients With Relapsed Acute Myeloid Leukemia (NCT01870596) | National Cancer Institute (NCI) | 2013-05-01 |
| Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia (NCT01361464) | National Cancer Institute (NCI) | 2011-05-01 |
| Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia (NCT01307579) | Children's Oncology Group | 2011-04-04 |
| Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (NCT01238211) | National Cancer Institute (NCI) | 2010-12-14 |
| Azacitidine, Mitoxantrone Hydrochloride, and Etoposide in Treating Older Patients With Poor-Prognosis Acute Myeloid Leukemia (NCT01260714) | National Cancer Institute (NCI) | 2010-12-01 |
| Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers (NCT01254578) | National Cancer Institute (NCI) | 2010-11-24 |
| Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia (NCT01168219) | National Cancer Institute (NCI) | 2010-07-15 |
| Veliparib and Temozolomide in Treating Patients With Acute Leukemia (NCT01139970) | National Cancer Institute (NCI) | 2010-06-04 |
| Lenalidomide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia (NCT01132586) | National Cancer Institute (NCI) | 2010-05-01 |
| Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia (NCT00658814) | National Cancer Institute (NCI) | 2008-12-01 |
| Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders (NCT00588991) | National Cancer Institute (NCI) | 2008-02-04 |
| Decitabine as Maintenance Therapy After Standard Therapy in Treating Patients With Previously Untreated Acute Myeloid Leukemia (NCT00416598) | National Cancer Institute (NCI) | 2006-11-15 |
| Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase (NCT00383474) | National Cancer Institute (NCI) | 2006-08-01 |
| Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia (NCT00313586) | National Cancer Institute (NCI) | 2006-08-01 |
| Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases (NCT00351975) | National Cancer Institute (NCI) | 2006-06-01 |
| Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous Leukemia (NCT00217646) | National Cancer Institute (NCI) | 2005-10-01 |
| Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission (NCT00093470) | National Cancer Institute (NCI) | 2004-08-18 |